Jones, G and Wallace, T and McIntosh, MJ and Brockwell, L and Gomez-Reino, JJ and Sebba, A, Five-year efficacy and safety of Tocilizumab Monotherapy in patients with Rheumatoid Arthritis who were Methotrexate- and Biologic-naive or free of Methotrexate for 6 months: the AMBITION Study, Journal of Rheumatology, 44, (2) pp. 142-146. ISSN 0315-162X (2017) [Refereed Article]
Copyright 2017 The Journal of Rheumatology
METHODS: Patients with rheumatoid arthritis for whom biologics had not failed or who did not discontinue methotrexate because of lack of efficacy or tolerability were followed up for 5 years to assess the efficacy and serious adverse events (SAE) of tocilizumab (TCZ) monotherapy.
RESULTS: Longterm efficacy results showed that efficacy was maintained or improved for up to 264 weeks in patients receiving TCZ monotherapy. Serious infection was the most frequent SAE; no new safety signals were reported.
CONCLUSION: Longterm monotherapy with TCZ demonstrated continuing efficacy and safety.
|Item Type:||Refereed Article|
|Keywords:||biological therapy, methotrexate, clinical trials, disease activity, rheumatoid arthritis|
|Research Division:||Biomedical and Clinical Sciences|
|Research Group:||Clinical sciences|
|Research Field:||Rheumatology and arthritis|
|Objective Group:||Clinical health|
|Objective Field:||Clinical health not elsewhere classified|
|UTAS Author:||Jones, G (Professor Graeme Jones)|
|Year Published:||2017 (online first 2016)|
|Web of Science® Times Cited:||23|
|Deposited By:||Menzies Institute for Medical Research|
Repository Staff Only: item control page